Why Mitochondrial Therapy?

Mitochondria are the battery of the cell supplying cellular energy (ATP) to enable all the functionalities of life, such as proteins synthesis, DNA repair, waste removal, muscle contraction, etc. All degenerative diseases and aging start with damage to mitochondria once energy production is depleted, the cell starts to degenerate.

Mitochondrial therapy is the most transformative and impactful field for human health and longevity.

Leadership, Business & Funding

- Experienced leadership – proven track record of product development from inception to exit
- Extensive funding experience – millions USD raised
- Extensive experience in complex deals: M&A, IPO, licensing
- Strategic IP construction and management of large portfolios
- 1.5 Million USD invested by founders
- All equity is held by the founders
- Strategic business development plan to ensure fast revenue and growth

Value Drivers

- Controlling manufacturing
- Extensive IP development
- Early licensing income
- Multiple out-licenses across industries
- Pre-clinical and clinical validation by partners

Cellergy is Closing the Gap to making mitochondria a viable commercial product

Proprietary Source and Process
Non-transformed source, high-quality, scalable, cost-effective

Manufacturing
massive quantities, down stream purification process in place, formulation for both local and systemic repeated administration
Next – the world’s first GMP production facility

Allogeneic
AI based software for donor/recipient matching output

We are unlocking an entire field of aging/longevity related therapies

Dev/Business Milestones

<table>
<thead>
<tr>
<th>Timeframe</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6 months</td>
<td>Early licensing income and validation by licensees</td>
</tr>
<tr>
<td>12 months</td>
<td>Building manufacturing capabilities while developing selected indications</td>
</tr>
<tr>
<td>18 months</td>
<td>Mid-scale Non-GMP mitochondria ready for pre-clinical collaborations</td>
</tr>
<tr>
<td>24 months</td>
<td>First out-license deal</td>
</tr>
<tr>
<td>30 months</td>
<td>First IND by licensee</td>
</tr>
<tr>
<td>60 months</td>
<td>Launch of approved pharma product by licensee</td>
</tr>
</tbody>
</table>

Closing the Gap in Mitochondrial Therapy